IART Integra Lifesciences Holdings Corp

Price (delayed)

$36.88

Market cap

$2.88B

P/E Ratio

29.98

Dividend/share

N/A

EPS

$1.23

Enterprise value

$4.3B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
The stock's price to earnings (P/E) is 34% less than its 5-year quarterly average of 47.4 but 14% more than its last 4 quarters average of 27.6
Integra Lifesciences Holdings's net income has decreased by 42% YoY and by 23% from the previous quarter
IART's EPS is down by 41% year-on-year and by 23% since the previous quarter

Key stats

What are the main financial stats of IART
Market
Shares outstanding
78.18M
Market cap
$2.88B
Enterprise value
$4.3B
Valuations
Price to book (P/B)
1.9
Price to sales (P/S)
1.91
EV/EBIT
25.74
EV/EBITDA
14.77
EV/Sales
2.79
Earnings
Revenue
$1.54B
EBIT
$166.94M
EBITDA
$290.86M
Free cash flow
$120.9M
Per share
EPS
$1.23
Free cash flow per share
$1.52
Book value per share
$19.4
Revenue per share
$19.36
TBVPS
$20.53
Balance sheet
Total assets
$3.74B
Total liabilities
$2.16B
Debt
$1.69B
Equity
$1.58B
Working capital
$671.52M
Liquidity
Debt to equity
1.07
Current ratio
2.89
Quick ratio
1.49
Net debt/EBITDA
4.86
Margins
EBITDA margin
18.9%
Gross margin
58.9%
Net margin
6.5%
Operating margin
9.3%
Efficiency
Return on assets
2.7%
Return on equity
6%
Return on invested capital
6.4%
Return on capital employed
4.9%
Return on sales
10.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
-4.63%
1 week
-17.77%
1 month
-11.94%
1 year
-33.69%
YTD
-15.32%
QTD
-15.32%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.54B
Gross profit
$908.33M
Operating income
$143.32M
Net income
$100.85M
Gross margin
58.9%
Net margin
6.5%
Integra Lifesciences Holdings's net income has decreased by 42% YoY and by 23% from the previous quarter
The net margin has declined by 41% year-on-year and by 24% since the previous quarter
IART's operating margin is down by 37% year-on-year and by 21% since the previous quarter
The operating income has declined by 37% year-on-year and by 21% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
P/E
29.98
P/B
1.9
P/S
1.91
EV/EBIT
25.74
EV/EBITDA
14.77
EV/Sales
2.79
IART's EPS is down by 41% year-on-year and by 23% since the previous quarter
The stock's price to earnings (P/E) is 34% less than its 5-year quarterly average of 47.4 but 14% more than its last 4 quarters average of 27.6
The P/B is 36% lower than the 5-year quarterly average of 3.1 and 13% lower than the last 4 quarters average of 2.3
The equity has declined by 8% year-on-year and by 6% since the previous quarter
The price to sales (P/S) is 35% less than the 5-year quarterly average of 3.1 and 20% less than the last 4 quarters average of 2.5

Efficiency

How efficient is Integra Lifesciences Holdings business performance
Integra Lifesciences Holdings's return on equity has decreased by 42% YoY and by 21% QoQ
IART's ROA is down by 41% YoY and by 23% QoQ
IART's return on invested capital is down by 35% year-on-year and by 20% since the previous quarter
IART's return on sales is down by 33% year-on-year and by 19% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 73% higher than its total liabilities
IART's quick ratio is down by 40% YoY
The current ratio has declined by 26% year-on-year but it has grown by 4% since the previous quarter
The debt is 7% greater than the equity
Integra Lifesciences Holdings's debt to equity has increased by 13% QoQ and by 8% YoY
The equity has declined by 8% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.